These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38471713)

  • 1. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
    Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.
    Kim JH; Kim YM; Choi D; Jo SB; Park HW; Hong SW; Park S; Kim S; Moon S; You G; Kang YW; Park Y; Lee BH; Lee SW
    Clin Transl Immunology; 2020; 9(9):e1168. PubMed ID: 32994996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions.
    Kim S; Lee SW; Koh JY; Choi D; Heo M; Chung JY; Lee BH; Yang SH; Sung YC; Lee H; Shin EC; Park SH
    Blood Adv; 2022 Dec; 6(23):6093-6107. PubMed ID: 36206199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity.
    Lee JY; Lee E; Hong SW; Kim D; Eunju O; Sprent J; Im SH; Lee YJ; Surh CD
    Oncoimmunology; 2020; 9(1):1681869. PubMed ID: 32002288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.
    Lee KJ; Choi D; Tae N; Song HW; Kang YW; Lee M; Moon D; Oh Y; Park S; Kim JH; Jeong S; Yang J; Park U; Hong DH; Byun MS; Park SH; Sohn J; Park Y; Im SK; Choi SS; Kim DH; Lee SW
    Cell Rep Med; 2024 May; 5(5):101567. PubMed ID: 38744277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
    LaPorte KM; Hernandez R; Santos Savio A; Malek TR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
    Li D; Liang T; Hutchins LE; Wolfarth AA; Ferrando-Martinez S; Lee BH; Ho M
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects.
    Lee SW; Choi D; Heo M; Shin EC; Park SH; Kim SJ; Oh YK; Lee BH; Yang SH; Sung YC; Lee H
    Clin Transl Sci; 2020 Nov; 13(6):1161-1169. PubMed ID: 32339447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation.
    Lee J; Lee K; Bae H; Lee K; Lee S; Ma J; Jo K; Kim I; Jee B; Kang M; Im SJ
    Front Immunol; 2023; 14():1117092. PubMed ID: 37409128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.
    Khan SM; Desai R; Coxon A; Livingstone A; Dunn GP; Petti A; Johanns TM
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
    Campian JL; Ghosh S; Kapoor V; Yan R; Thotala S; Jash A; Hu T; Mahadevan A; Rifai K; Page L; Lee BH; Ferrando-Martinez S; Wolfarth AA; Yang SH; Hallahan D; Chheda MG; Thotala D
    Clin Cancer Res; 2022 Mar; 28(6):1229-1239. PubMed ID: 35031547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The primordial differentiation of tumor-specific memory CD8
    Huang Q; Wu X; Wang Z; Chen X; Wang L; Lu Y; Xiong D; Liu Q; Tian Y; Lin H; Guo J; Wen S; Dong W; Yang X; Yuan Y; Yue Z; Lei S; Wu Q; Ran L; Xie L; Wang Y; Gao L; Tian Q; Zhou X; Sun B; Xu L; Tang Z; Ye L
    Cell; 2022 Oct; 185(22):4049-4066.e25. PubMed ID: 36208623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive profile of TCF1
    Wang D; Fang J; Wen S; Li Q; Wang J; Yang L; Dai W; Lu H; Guo J; Shan Z; Xie W; Liu X; Wen L; Shen J; Wang A; Chen Q; Wang Z
    Int J Oral Sci; 2022 Feb; 14(1):8. PubMed ID: 35153298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
    Kim MY; Jayasinghe R; Devenport JM; Ritchey JK; Rettig MP; O'Neal J; Staser KW; Kennerly KM; Carter AJ; Gao F; Lee BH; Cooper ML; DiPersio JF
    Nat Commun; 2022 Jun; 13(1):3296. PubMed ID: 35697686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
    Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
    J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.